Aurgalys - Biocorp Production SA (ALCOR) Biocorp, se connecter pour mieux se soigner

Report

Aurgalys

Biocorp, se connecter pour mieux se soigner

â€‹Biocorp, acteur de la santÃ© connectÃ©e, s'inscrit depuis 2004 dans la chaÃ®ne de valeur des entreprises pharmaceutiques. Biocorp dÃ©veloppe, produit et commercialise des dispositifs mÃ©dicaux dont la gÃ©nÃ©ration la plus rÃ©cente s'adresse au nouveau marchÃ© de l'e-santÃ©. Nous initions la couverture de Biocorp avec un objectif de 17,59â‚¬/action, soit une capitalisation boursiÃ¨re estimÃ©e Ã 52,03Mâ‚¬. Cette valorisation a Ã©tÃ© effectuÃ©e sur la base de son activitÃ© historique dans l'injection plastique pour des produits Ã destination des laboratoires pharmaceutiques, ainsi que sur ses produits de dispostifs mÃ©dicaux connectÃ©s.

10/09/2015 1 FR

Underlying

Biocorp Production SA

Biocorp Production SA is a France-based company, which is specialised in the development and manufacturing of medical and drug delivery devices.

See profile

FR0012788065 Euronext Paris France

Provider

Aurgalys

First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.

See profile

Other Reports on these Companies

BusinessWire

BIOCORP : Fin du contrat de liquidité conclu avec la société de Bourse Gilbert Dupont

ISSOIRE, France--(BUSINESS WIRE)-- Regulatory News: BIOCORP (FR0012788065 – ALCOR / Éligible PEA‐PME), société française spécialisée dans le développement et la fabrication de dispositifs médicaux et de solutions connectées dans le domaine de la santé, et la société de Bourse Gilbert Dupont ont mis fin au contrat de liquidité conclu le 3 février 2020. Cette résiliation a pris effet le 28 septembre 2023 au soir. A cette date, les moyens suivants figuraient au compte de liquidité : Nombre d’actions : 9 724 Solde en espèces : 238 695,44 € Il est rappelé que, lors du dernier bilan s...

October 2, 2023 October 2, 2023 1 FR

BusinessWire

BIOCORP : COMMUNIQUE EN DATE DU 2 OCTOBRE 2023

PARIS--(BUSINESS WIRE)-- Regulatory News: Biocorp (Paris:ALCOR) : Ce communiqué ne constitue pas une offre d’acquérir des titres. COMMUNIQUE EN DATE DU 2 OCTOBRE 2023 RELATIF A LA MISE EN ŒUVRE DU RETRAIT OBLIGATOIRE VISANT LES ACTIONS DE LA SOCIETE Biocorp Production CONSECUTIVEMENT A L’OFFRE PUBLIQUE D’ACHAT INITIEE PAR NOVO NORDISK REGION EUROPE A/S MONTANT DE L’INDEMNISATION : 35 euros par action Biocorp Production Autorité des Marchés Financiers Le présent communiqué de presse a été établi et diffusé par NOVO NORDISK REGION EUROPE A/S, en application des disposition...

October 2, 2023 October 2, 2023 1 FR

BusinessWire

Biocorp Production : COMMUNIQUE DU 6 SEPTEMBRE 2023 RELATIF A L’OFFRE PUBLIQUE D’ACHAT SIMPLIFIEE VISANT LES ACTIONS DE LA SOCIETE BIOCORP

ISSOIRE, France--(BUSINESS WIRE)-- Regulatory News: Biocorp Production (Paris:ALCOR) : COMMUNIQUE DU 6 SEPTEMBRE 2023 RELATIF A L’OFFRE PUBLIQUE D’ACHAT SIMPLIFIEE VISANT LES ACTIONS DE LA SOCIETE BIOCORP INITIEE PAR LA SOCIETE NOVO NORDISK REGION EUROPE A/S MISE A DISPOSITION DE LA NOTE D’INFORMATION EN REPONSE ET DU DOCUMENT « AUTRES INFORMATIONS » RELATIF AUX CARACTERISTIQUES NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LA SOCIETE BIOCORP PRODUCTION TERMES DE L’OFFRE : PRIX DE L’OFFRE : 35 euros par action Biocorp Production DUREE DE L’OFFRE : 15 jours de négociation L...

September 6, 2023 September 6, 2023 1 FR

Biocorp could achieve decisive milestones in 2017

For the past 2 years, Biocorp has initiated major business transformations in order to become a key player in the booming market of connected health. The company has developed a range of connected devices addressing major healthcare issues. The company made significant advances in 2016 by signing 4 partnerships agreements with pharmaceutical players. Based on these agreements, Biocorp and its partners initiated preliminary studies assessing the feasibility and the performance of Biocorpâ€™s connected devices in various indications. Since several milestones are expected on these studies in 201...

January 31, 2017 January 31, 2017 8 EN

Christophe DOMBU

Christophe DOMBU

Implanetâ€™s Jazz sales up 18% in 2016

â€‹ Implanet published its 2016 sales, confirming the good dynamics of its marketing activity (+18% compared to 2015, from â‚¬6.7 M to â‚¬7.8 M). The company benefits from the growing adoption of its lead product, the Jazz Band, especially in France and the US. Given the companyâ€™s efforts to further accelerate the adoption of Jazz, we believe that the company has the means to maintain this trend in 2017. Although the reported sales are slightly below our forecast, we remain confident on the company's outlook and maintain our target price at â‚¬ 2.34 / share.

January 16, 2017 January 16, 2017 2 EN

Christophe DOMBU

Christophe DOMBU

Implanet confirms clinical benefits of Jazz implants after three years of patient follow-up

â€‹Implanet released additional clinical data showing the good performance of the Jazz band implant in correcting large spine deformitiesinadolescents.Datawerepublishedinawhitepaper by French KOLs, giving Implanet additional arguments to convince more surgeons to adopt the companyâ€™s product, while expandingitsscopeofapplication.Implanet recently secured a â‚¬ 6.9Mfollow-onfinancing.Theoperationreceivedastrongsupportfromseinstitutionalinvestorsdespitedifficultmarketconditions.The funds will supportthestrategicdeploymentinitiated by the company to accelerate sales of its spinal implants, which...

December 9, 2016 December 9, 2016 4 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Biocorp, se connecter pour mieux se soigner

BIOCORP : Fin du contrat de liquidité conclu avec la société de Bourse Gilbert Dupont

BIOCORP : COMMUNIQUE EN DATE DU 2 OCTOBRE 2023

Biocorp Production : COMMUNIQUE DU 6 SEPTEMBRE 2023 RELATIF A L’OFFRE PUBLIQUE D’ACHAT SIMPLIFIEE VISANT LES ACTIONS DE LA SOCIETE BIOCORP

Biocorp could achieve decisive milestones in 2017

Implanetâ€™s Jazz sales up 18% in 2016

Implanet confirms clinical benefits of Jazz implants after three years of patient follow-up

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe